The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Provider mix and costs associated with treatment of patients with bone metastases secondary to prostate cancer.
Kenneth M. Shermock
Consultant or Advisory Role - Bayer
Sean D Sullivan
Consultant or Advisory Role - Bayer
Scott David Ramsey
Consultant or Advisory Role - Bayer
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer